Innospera is a privately-owned biotech company near clinical stage, developing small molecule modulators of 7-transmembrane receptors involved in a broad range of chronic and fibrotic conditions. The company’s lead drug candidates target key G-protein coupled receptors (GPCR) involved in fibroaging and inflammaging, including idiopathic pulmonary fibrosis (IPF), a condition with dire short-term prognosis. Innospera also develops multiple other modulators with promising potency in other medical conditions with pressing unmet needs. For more information, visit innospera.com
Company Details
- Employees
- 7
- Address
- Montreal, Ca
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.innospera.com
- Keywords
- Mirabel.
- HQ
- Montreal
Innospera Pharma Questions
Innospera Pharma's website is http://www.innospera.com
Innospera Pharma's LinkedIn profile is https://ca.linkedin.com/company/innospera-pharma
Innospera Pharma has
7 employees.
View email and phone details for 7
employees at Innospera Pharma.
Innospera Pharma's industry is
Biotechnology Research
Innospera Pharma's top competitors are
Theratechnologies Inc.,
Exka Inc.,
Inversago Pharma,
Jrf Global,
Seido Capital,
Investissement Québec,
Halo Pharmaceutical, Inc.,
Jubilant Hollisterstier Cmo,
Congruence Therapeutics,
Noa Therapeutics.
Innospera Pharma's categories are Biotechnology Research
